LLY-283
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 532772

CAS#: 2040291-27-6

Description: LLY-283 is a potent and selective SAM-competitive chemical probe for PRMT5 (protein arginine methyltransferase 5).

Chemical Structure

img
LLY-283
CAS# 2040291-27-6
Product data Instruction

Theoretical Analysis

MedKoo Cat#: 532772
Name: LLY-283
CAS#: 2040291-27-6
Chemical Formula: C17H18N4O4
Exact Mass: 342.13
Molecular Weight: 342.355
Elemental Analysis: C, 59.64; H, 5.30; N, 16.37; O, 18.69

Price and Availability

Size Price Availability Quantity
10mg USD 385 2 Weeks
Bulk inquiry

Synonym: LLY-283; LLY 283; LLY283; LM-5179; LM 5179; LM5179.

IUPAC/Chemical Name: (2R,3R,4S,5R)-2-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-5-[(R)-hydroxy(phenyl)methyl]oxolane-3,4-diol

InChi Key: WWOOWAHTEXIWBO-QFRSUPTLSA-N

InChi Code: InChI=1S/C17H18N4O4/c18-15-10-6-7-21(16(10)20-8-19-15)17-13(24)12(23)14(25-17)11(22)9-4-2-1-3-5-9/h1-8,11-14,17,22-24H,(H2,18,19,20)/t11-,12+,13-,14-,17-/m1/s1

SMILES Code: O[C@H]1[C@H](N2C=CC3=C(N)N=CN=C32)O[C@H]([C@H](O)C4=CC=CC=C4)[C@H]1O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Product Data:
Product Data
Instruction:
View handling instruction
Biological target: LLY-283 is a potent, selective and oral protein arginine methyltransferase 5 (PRMT5) inhibitor, with an IC50 of 22 nM and a Kd of 6 nM for PRMT5:MEP50 complex, and shows antitumor activity.
In vitro activity: ROS experiments confirmed that LLY-283 could rescue cisplatin-induced oxidative damage to auditory cells. TUNEL experiments confirmed that LLY-283 could protect cisplatin-induced apoptosis of auditory cells. Meanwhile, LLY-283 could inhibit the expression of PRMT5 in auditory cells induced by cisplatin. Reference: J Clin Lab Anal. 2022 Feb;36(2):e24176. https://pubmed.ncbi.nlm.nih.gov/34997776/
In vivo activity: The aim of this study was to investigate the effect of LLY-283, a selective inhibitor of protein arginine methyltransferase 5 (PRMT5), on a noise-induced hearing loss (NIHL) mouse model and to identify a potential target for a therapeutic intervention against NIHL. LLY-283 pretreatment before noise exposure notably decreased 4-HNE and caspase-3/7 levels in the cochlear HCs. Reference: Ecotoxicol Environ Saf. 2022 Sep 15;243:113992. https://pubmed.ncbi.nlm.nih.gov/35994911/

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
Water 4.3 12.52

Preparing Stock Solutions

The following data is based on the product molecular weight 342.36 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol: 1. Zhao B, Zhang D, Sun Y, Lei M, Zeng P, Wang Y, Hong Y, Jiao Y, Cai C. Explore the effect of LLY-283 on the ototoxicity of auditory cells caused by cisplatin: A bioinformatic analysis based on RNA-seq. J Clin Lab Anal. 2022 Feb;36(2):e24176. doi: 10.1002/jcla.24176. Epub 2022 Jan 8. PMID: 34997776; PMCID: PMC8842247. 2. Sachamitr P, Ho JC, Ciamponi FE, Ba-Alawi W, Coutinho FJ, Guilhamon P, Kushida MM, Cavalli FMG, Lee L, Rastegar N, Vu V, Sánchez-Osuna M, Coulombe-Huntington J, Kanshin E, Whetstone H, Durand M, Thibault P, Hart K, Mangos M, Veyhl J, Chen W, Tran N, Duong BC, Aman AM, Che X, Lan X, Whitley O, Zaslaver O, Barsyte-Lovejoy D, Richards LM, Restall I, Caudy A, Röst HL, Bonday ZQ, Bernstein M, Das S, Cusimano MD, Spears J, Bader GD, Pugh TJ, Tyers M, Lupien M, Haibe-Kains B, Artee Luchman H, Weiss S, Massirer KB, Prinos P, Arrowsmith CH, Dirks PB. PRMT5 inhibition disrupts splicing and stemness in glioblastoma. Nat Commun. 2021 Feb 12;12(1):979. doi: 10.1038/s41467-021-21204-5. PMID: 33579912; PMCID: PMC7881162. 3. Liu C, Tang D, Zheng Z, Lu X, Li W, Zhao L, He Y, Li H. A PRMT5 inhibitor protects against noise-induced hearing loss by alleviating ROS accumulation. Ecotoxicol Environ Saf. 2022 Sep 15;243:113992. doi: 10.1016/j.ecoenv.2022.113992. Epub 2022 Aug 19. PMID: 35994911. 4. Bonday ZQ, Cortez GS, Grogan MJ, Antonysamy S, Weichert K, Bocchinfuso WP, Li F, Kennedy S, Li B, Mader MM, Arrowsmith CH, Brown PJ, Eram MS, Szewczyk MM, Barsyte-Lovejoy D, Vedadi M, Guccione E, Campbell RM. LLY-283, a Potent and Selective Inhibitor of Arginine Methyltransferase 5, PRMT5, with Antitumor Activity. ACS Med Chem Lett. 2018 Apr 23;9(7):612-617. doi: 10.1021/acsmedchemlett.8b00014. PMID: 30034588; PMCID: PMC6047023.
In vitro protocol: 1. Zhao B, Zhang D, Sun Y, Lei M, Zeng P, Wang Y, Hong Y, Jiao Y, Cai C. Explore the effect of LLY-283 on the ototoxicity of auditory cells caused by cisplatin: A bioinformatic analysis based on RNA-seq. J Clin Lab Anal. 2022 Feb;36(2):e24176. doi: 10.1002/jcla.24176. Epub 2022 Jan 8. PMID: 34997776; PMCID: PMC8842247. 2. Sachamitr P, Ho JC, Ciamponi FE, Ba-Alawi W, Coutinho FJ, Guilhamon P, Kushida MM, Cavalli FMG, Lee L, Rastegar N, Vu V, Sánchez-Osuna M, Coulombe-Huntington J, Kanshin E, Whetstone H, Durand M, Thibault P, Hart K, Mangos M, Veyhl J, Chen W, Tran N, Duong BC, Aman AM, Che X, Lan X, Whitley O, Zaslaver O, Barsyte-Lovejoy D, Richards LM, Restall I, Caudy A, Röst HL, Bonday ZQ, Bernstein M, Das S, Cusimano MD, Spears J, Bader GD, Pugh TJ, Tyers M, Lupien M, Haibe-Kains B, Artee Luchman H, Weiss S, Massirer KB, Prinos P, Arrowsmith CH, Dirks PB. PRMT5 inhibition disrupts splicing and stemness in glioblastoma. Nat Commun. 2021 Feb 12;12(1):979. doi: 10.1038/s41467-021-21204-5. PMID: 33579912; PMCID: PMC7881162.
In vivo protocol: 1. Liu C, Tang D, Zheng Z, Lu X, Li W, Zhao L, He Y, Li H. A PRMT5 inhibitor protects against noise-induced hearing loss by alleviating ROS accumulation. Ecotoxicol Environ Saf. 2022 Sep 15;243:113992. doi: 10.1016/j.ecoenv.2022.113992. Epub 2022 Aug 19. PMID: 35994911. 2. Bonday ZQ, Cortez GS, Grogan MJ, Antonysamy S, Weichert K, Bocchinfuso WP, Li F, Kennedy S, Li B, Mader MM, Arrowsmith CH, Brown PJ, Eram MS, Szewczyk MM, Barsyte-Lovejoy D, Vedadi M, Guccione E, Campbell RM. LLY-283, a Potent and Selective Inhibitor of Arginine Methyltransferase 5, PRMT5, with Antitumor Activity. ACS Med Chem Lett. 2018 Apr 23;9(7):612-617. doi: 10.1021/acsmedchemlett.8b00014. PMID: 30034588; PMCID: PMC6047023.

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1. SGC. LLY-283 A Chemical Probe For PRMT5. Accessed on 05/04/2017. Modified on 05/04/2017. thesgc.org, http://www.thesgc.org/chemical-probes/LLY-283